Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
monoclonal antibody
Biotech
Sanofi's hopes for $1.1B Kymab drug dented after ph. 2 asthma fail
The highest dose of amlitelimab missed the primary endpoint of reducing severe asthma exacerbations at Week 48.
James Waldron
Apr 15, 2025 7:34am
Genmab axes anti-CD38 antibody after losing J&J support
Mar 10, 2025 2:13pm
Windward generates $200M with Novo Holdings, OrbiMed in tow
Jan 10, 2025 10:02am
Omeros stock up after data analysis spurs BLA resubmission plan
Dec 19, 2024 10:54am
Roivant’s midstage asset fails to show benefit in lung disease
Dec 3, 2024 10:32am
Jade pockets Aerovate in reverse merger
Oct 31, 2024 3:03pm
